Zamto-cel shows promise in interim results from phase 2 pivotal study
In the video interview, Overstijns and Dr. Wijatyk discuss interim results from the phase 2 pivotal Study (DALY II USA) evaluating zamtocabtagene autoleucel
In the video interview, Overstijns and Dr. Wijatyk discuss interim results from the phase 2 pivotal Study (DALY II USA) evaluating zamtocabtagene autoleucel
The novel CAR-T demonstrated robust and highly selective eradication of low- and high- mutCALR expressing human cell lines in vitro.
For SOHO, 2024 was a year of firsts and continued growth of the society worldwide.
The Board of Directors and the Steering Committee of the Society of Hematologic Oncology (SOHO) are pleased to announce that Phillip Scheinberg, MD,
Trem-cel enables repeated post-HCT maintenance dosing of gemtuzumab ozogamicin in patients with high-risk AML.
Recorded at the 66th American Society of Hematology Annual Meeting and Exposition, Yuan Yao, MD, MS, discusses the ASH abstract (No.397) titled, “Prevalence,
ASH-Gbot, an AI-driven chatbot trained on the American Society of Hematology (ASH) guidelines, is able to deliver disease-specific advice for hematological conditions with
After being postponed due to the war in the Middle East, SOHO MENA is very excited to announce that the hybrid meeting will
In this video filmed at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, Valeria Santini, MD, an associate professor of
Iryna Kriachok, MD, PhD, of the National Cancer Institute in Kyiv, Ukraine, explains in both Ukrainian and English why being invited to the